Nestle may sell allergy unit as CEO reverses course, Bloomberg reports

Nestle put its Palforzia peanut-allergy treatment up for sale only two years after buying it, as Chief Executive Officer Mark Schneider reverses course on one of his biggest acquisitions beyond the Swiss company’s traditional food and beverage operations, Bloomberg’s Dasha Afanasieva reports. Schneider told investors Tuesday that Nestle is trying to correct mistakes quickly and aims for consistent results in the coming years even as the market becomes more volatile. He set new targets for earnings growth and profitability through 2025, the author notes. Reference Link